← Back to Search

Cognitive Bias Modification for Obsessive-Compulsive Disorder

N/A
Recruiting
Research Sponsored by Mclean Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Adults (> 18 years old)
Primary diagnosis of OCD (as measured by a score of >16 on the Y-BOCS and a clinical diagnosis of OCD by their treatment team)
Must not have
Psychotic disorder diagnosis
Currently experiencing acute symptoms of psychosis
Timeline
Screening 3 weeks
Treatment Varies
Follow Up time frame: weeks 0, 2, 4, and 8
Awards & highlights

Summary

This trial will test whether CBM-I is a feasible and acceptable augmentation to treatment as usual for OCD, and will examine preliminary efficacy by examining clinical outcomes associated with CBM-I.

Who is the study for?
This trial is for adults over 18 with a primary diagnosis of OCD, confirmed by specific clinical assessments. Participants must be able to complete computer tasks and consent to the main study protocol. Those with acute psychosis or a psychotic disorder cannot join.Check my eligibility
What is being tested?
The trial tests Cognitive Bias Modification for Interpretation (CBM-I), a digital intervention aimed at changing interpretation bias in OCD patients, against psychoeducation. It will assess CBM-I's feasibility, acceptability, and impact on OCD when added to usual treatment.See study design
What are the potential side effects?
Since CBM-I involves computer-based tasks and psychoeducation is informational, significant side effects are not anticipated. However, participants may experience discomfort or fatigue from focusing on a screen during sessions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am over 18 years old.
Select...
I have been diagnosed with OCD and my symptoms are moderate to severe.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have been diagnosed with a psychotic disorder.
Select...
I am currently experiencing severe symptoms of psychosis.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~time frame: weeks 0, 2, 4, and 8
This trial's timeline: 3 weeks for screening, Varies for treatment, and time frame: weeks 0, 2, 4, and 8 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in Average Score on Yale-Brown Obsessive Compulsive Scale
Secondary outcome measures
Change in Average Score on Obsessive Beliefs Questionnaire

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Cognitive bias modification with treatment as usualExperimental Treatment1 Intervention
Participants in this group will receive usual treatment in the program up to 12 sessions of a digital cognitive training targeting interpretation bias
Group II: Psychoeducation with treatment as usualPlacebo Group1 Intervention
Participants in this group will receive usual treatment in the program up to 12 sessions of digitized psychoeducation

Find a Location

Who is running the clinical trial?

Mclean HospitalLead Sponsor
213 Previous Clinical Trials
21,555 Total Patients Enrolled
9 Trials studying Obsessive-Compulsive Disorder
637 Patients Enrolled for Obsessive-Compulsive Disorder

Media Library

Psychoeducation Clinical Trial Eligibility Overview. Trial Name: NCT05224414 — N/A
Obsessive-Compulsive Disorder Research Study Groups: Cognitive bias modification with treatment as usual, Psychoeducation with treatment as usual
Obsessive-Compulsive Disorder Clinical Trial 2023: Psychoeducation Highlights & Side Effects. Trial Name: NCT05224414 — N/A
Psychoeducation 2023 Treatment Timeline for Medical Study. Trial Name: NCT05224414 — N/A
~50 spots leftby Aug 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top